ZIBOR 3.500 IU Solution for injection Ref.[10842] Active ingredients: Bemiparin

Source: Health Products Regulatory Authority (IE)  Revision Year: 2021  Publisher: Frosst Ibérica, S.A. Via Complutense 140, Alcalá de Henares, 28805 Madrid, Spain

Product name and form

Zibor 3,500 IU anti Xa/0.2 ml solution for injection in pre-filled syringes.

Pharmaceutical Form

Solution for injection in pre-filled syringes.

(Colourless or slightly yellowish, clear solution, free of visible particles)

Qualitative and quantitative composition

Bemiparin sodium: 3500 IU (anti Factor Xa*) per 0.2 ml pre-filled syringe (equivalent to 17500 IU (antiFactor Xa*) per millilitre solution for injection).

Potency is described in International anti-Factor Xa activity units (IU) of the 1st International Low Molecular Weight Heparin Reference Standard.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Bemiparin

Bemiparin is a LMWH obtained by depolymerization of heparin from porcine intestinal mucosa. Bemiparin has confirmed its antithrombotic activity and, at the recommended doses, it does not significantly prolong global clotting tests.

List of Excipients

Water for injections

Pack sizes and marketing

0.2 ml solution in pre-filled syringe (Type I glass) with a plunger rod (polypropylene), rubber plunger stopper (chlorobutyl) and injection needle (stainless steel). Packs of 2, 6, 10, 30 and 100 syringes.

In some package sizes, the prefilled syringe may be combined to a safety device system. For syringes with safety device system the needle must be oriented away from the user and anyone else who is present. The safety system is activated by pressing firmly on the plunger rod. The protective sleeve will automatically cover the needle and will produce an audible click which confirms the activation of the device.

Immediately, the syringe must be discarded by throwing it into the nearest sharps bin (the needle in). The container lid must be closed tightly and the container placed out of the reach of children.

Not all pack sizes may be marketed.

Marketing authorization holder

Frosst Ibérica, S.A. Via Complutense 140, Alcalá de Henares, 28805 Madrid, Spain

Marketing authorization dates and numbers

PA1769/001/002

Date of first authorisation: 03 May 2002

Date of last renewal: 09 March 2010

Drugs

Drug Countries
ZIBOR Estonia, Ireland, Lithuania, Poland, Romania, United Kingdom

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.